In this case, you should opt for a different kind of treatment
Mounjaro was approved first for type 2 diabetes, driven by strong clinical data showing improved glycemic control in diabetic patients
"Orforglipron 12 mg and 36 mg doses outperformed oral semaglutide 7 mg and 14 mg diabetes-related doses on every key endpoint we measured, including A1C and weight loss, with improvements appearing as early as four weeks and sustained throughout the study." Orforglipron also showed clinically meaningful improvements from baseline across key cardiovascular risk factors, including non-HDL cholesterol, HDL cholesterol, VLDL cholesterol, total cholesterol, systolic blood pressure and triglycerides
Raper SE, Wilson JM, Yudkoff M, Robinson MB, Ye X, Batshaw ML
(3) Small, frequent meals are commonly advised for early satiety or nausea